title: Perrigo
id: 3095103
Perrigo Company plc Hebrew is an American Irish registered manufacturer of private label over the counter pharmaceuticals and while of Perrigo s net sales are from the U S healthcare system Perrigo is legally headquartered in Ireland for tax purposes which accounts for of net sales In Perrigo completed the sixth largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U S corporate taxes Perrigo maintains its corporate headquarters in Grand Rapids Michigan within Michigan State University s Grand Rapids Innovation Park br Perrigo engages in the acquisition for repricing manufacture and sale of consumer healthcare products generic prescription drugs and active pharmaceutical ingredients APIs primarily in the United States from its base in Ireland On December Perrigo suffered its biggest one day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value br br br History br L Perrigo Company was founded in in Allegan Michigan by Luther and Charles Perrigo who ran a general store br In Perrigo had an initial public offering on Nasdaq br In March the firm acquired Agis Industries Limited traded as AGIS at the Tel Aviv Stock Exchange an Israel based generic pharmaceuticals company in an million transaction Agis was founded in by Mori Arkin who developed his father s small drug import business into a multinational generic pharmaceutical company As a result of the acquisition Arkin owned of Perrigo and was appointed as Vice Chairman of the company br In July Perrigo announced that it would execute a corporate tax inversion to Ireland in order to avoid U S corporate taxes via an billion acquisition of Irish based Elan Corporation As of November Perrigo is the sixth largest U S tax inversion in history Over of Perrigo s sales and an even greater percentage of Perrigo profits are from the U S healthcare system br In April Perrigo received an unsolicited buy out offer from Mylan of billion which was ultimately rejected by management and shareholders In May Perrigo investors sued the company over statements made during the Mylan bid which were said to have persuaded shareholders to vote against the deal In the months prior to this suit the company s chairman and CEO Joseph Papa who has been credited with fending off Mylan s bid left to take the CEO role at Valeant Upon Papa s departure John Hendrickson who was at the time the company s president took on the additional roles of chairman and CEO Hendrickson was succeeded by Uwe Roehrhoff in January Murray S Kessler succeeded Roehroff already in October of that same year As of July Patrick Lockwood Taylor is the current President and CEO br On December the Financial Times reported that the Irish Revenue Commissioners levied a billion not including penalties and interest Irish tax claim on Perrigo for unpaid capital gains tax CGT from the sale of Tysabri to Biogen by Elan which happened months before Perrigo s acquisition of Elan The claim is the second largest ever issued by the Revenue Commissioners in Irish history after Apple s billion Irish tax fine On December the Irish Times reported that Revenue claimed Perrigo owed CGT at a rate of as an asset sale however Perrigo claimed that the sale was part of Elan s normal trading income and was subject to the lower Irish corporate tax rate which Perrigo was able to reduce to using Ireland s multinational tax BEPS tools br In June Perrigo moved its corporate headquarters from Allegan to downtown Grand Rapids about miles north within Michigan State University s Grand Rapids Innovation Park The company still maintains offices and production at the Allegan campus br In its subsidiary HRA Pharma received approval from the FDA to sell an over the counter women s contraception drug called Opill br br br Acquisitions br On January the firm acquired Galpharm Healthcare Ltd a supplier of over the counter store brand pharmaceuticals in the United Kingdom On September the firm acquired J B Laboratories On October it acquired Laboratorios Diba S A enabling the company to market its products in Mexico On November it acquired Unico Holdings a manufacturer of store brand pediatric electrolytes enemas and feminine hygiene products for retail consumers in the U S br On March the firm acquired Orion Laboratories Pty Ltd a supplier of over the counter OTC store brand pharmaceutical products in Australia and New Zealand On March it acquired PBM Holdings Inc a producer of over the counter store brand infant formula and baby foods in the United States Canada Mexico and China br On January the firm announced that it would acquire Paddock Laboratories Inc with the deal expected to close in fiscal br In September Perrigo announced its intention to enter the animal wellness category by acquiring the assets of Sergeant s Pet Care Products Inc a privately held manufacturer of over the counter companion animal healthcare products br On February Perrigo announced the completion of the acquisition of Rosemont Pharmaceuticals Ltd a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations br On July the firm announced that it would acquire lan a pharmaceutical firm based in Dublin The lan acquisition enabled Perrigo to reincorporate as an Irish company using lan s headquarters although the executive offices remained in Allegan lowering its effective tax rate called a tax inversion br In November Perrigo announced it had agreed to buy Belgian health products provider Omega Pharma approximately billion billion The transaction was completed in March br In August the company announced it would acquire US national distributor of over the counter medicines Geiss Destin Dunn br In May Perrigo announced it would acquire Ranir Global Holdings LLC boosting its oral self care offering with the transaction valued at million br In February announced that it has reached an agreement to acquire the oral care assets of High Ridge Brands for million br In March Perrigo confirmed it would sell off its generics business to Altaris Capital Partners for billion In September the business announced it would acquire HRA Pharma from investment firms Astorg and Goldman Sachs Asset Management for billion and completed the acquisition in April br br br Acquisition history br The following is an illustration of the company s major mergers and acquisitions and historical predecessors this is not a comprehensive list br br br Segments br The company operates in three segments Consumer Self care Americas Rx Pharmaceuticals and Consumer Self Care International The Consumer Self care Americas segment produces over the counter pharmaceutical and nutritional products in the United States the United Kingdom and Mexico This segment offers analgesic cough cold allergy sinus gastrointestinal smoking cessation first aid antacids hemorrhoidal remedies motion sickness sleep aid products feminine hygiene products vitamin and nutritional supplement products br The Rx Pharmaceuticals segment produces generic prescription drugs in the United States This segment provides creams ointments lotions gels and solutions as well as nasal sprays foams and transdermal devices Believing that Rx business has the potential to realize greater value outside of Perrigo board okays separation of prescription pharma business on August br The Consumer Self Care International CSCI segment develops manufactures markets and distributes well known European self care brands in the natural health and vitamins cough cold and allergy oral care smoking cessation personal care and derma therapeutics and lifestyle categories br br br See also br Corporate tax inversions br Ireland as a tax haven br br br br br br External links br Official website br LinkedIn Page br Business data for Perrigo 